Beilu Pharma(SZ:300016) Zheng Quan Zhi Xing·2025-08-03 16:18Core Viewpoint - The company announces the mandatory redemption of its convertible bonds ("北陆转债") at a price of 101.64 CNY per bond, urging investors to convert their bonds before the deadline to avoid potential losses due to the significant difference between the market price and the redemption price [1][2][8]. Summary by Sections Convertible Bond Basic Information - The total issuance of the convertible bonds was 500 million CNY, approved by the China Securities Regulatory Commission [2]. - The conversion period for the bonds is from June 11, 2021, to December 6, 2026 [2]. Conversion Price Adjustments - The initial conversion price was set at 11.41 CNY per share, which was later adjusted downwards to 8.75 CNY due to market conditions and corporate actions [3][4][5]. - The current conversion price is 7.02 CNY per share, effective from May 19, 2025 [6]. Conditional Redemption Terms - The company has the right to redeem the bonds if the stock price exceeds 130% of the conversion price for 15 trading days within a 30-day period [7]. - The redemption condition was triggered as the stock price reached 9.13 CNY, which is 130% of the conversion price [8]. Redemption Implementation - The redemption price is set at 101.64 CNY per bond, which includes accrued interest [9]. - The redemption process will begin on July 31, 2025, with trading of the bonds ceasing on that date, and conversion ceasing on August 5, 2025 [9][10]. Shareholder Actions and Compliance - Shareholders must process their conversion requests through their respective securities firms, and the minimum conversion unit is one share [10]. - The company has confirmed that there were no transactions of the bonds by major shareholders in the six months prior to the redemption condition being met [9].